The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons

Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving ch...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2011-02, Vol.29 (9), p.1844-1849
Hauptverfasser: Katayose, Masahiko, Hosoya, Mitsuaki, Haneda, Takashi, Yamaguchi, Hideo, Kawasaki, Yukihiko, Sato, Masatoki, Wright, Peter F
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1849
container_issue 9
container_start_page 1844
container_title Vaccine
container_volume 29
creator Katayose, Masahiko
Hosoya, Mitsuaki
Haneda, Takashi
Yamaguchi, Hideo
Kawasaki, Yukihiko
Sato, Masatoki
Wright, Peter F
description Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature >38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.
doi_str_mv 10.1016/j.vaccine.2010.12.049
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_864961636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X10018220</els_id><sourcerecordid>864961636</sourcerecordid><originalsourceid>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhiMEokvhJ4AiIcQpy4xjO86FClV8SZU4UCRultcZq16yTrGTiPLrcbSBol56suV53hnPvFMUzxG2CCjf7LezsdYH2jJY3tgWePug2KBq6ooJVA-LDTDJK47w_aR4ktIeAESN7ePihCG2QgHbFMPlFZXkHNnRzxQopXJw5Rj9bHoKY-mDWSJmpC7fXT9R-G3KtXR-Ke2V77tIoRxmimXyv0o7hER2WvL9J0lkUg48LR450yd6tp6nxbcP7y_PP1UXXz5-Pn93UVnRiLFypBpldxK5YKa2ZIRD14EC2alaNiB3UrYtdyTazmHHLai2FpzbBluinalPi9fHvNdx-DlRGvXBJ0t9bwINU9JK8lairOX9pAAhoWY8ky_vkPthiiG3oZG3ChEkikyJI2XjkFIkp6-jP5h4oxH0Yp3e63V-erFOI9PZuqx7sWafdgfq_qn-epWBVytgkjW9iyZYn265WjXI5MKdHTnK8509RZ2sp2Cp8zHbrLvB3_uVt3cy2N4Hn4v-oBtKt13rlAX667Jny5ohACrGoP4Dao_PtQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1498110615</pqid></control><display><type>article</type><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</creator><creatorcontrib>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</creatorcontrib><description>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature &gt;38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2010.12.049</identifier><identifier>PMID: 21195802</identifier><identifier>CODEN: VACCDE</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Age ; Age Factors ; Allergy and Immunology ; Applied microbiology ; Biological and medical sciences ; Child, Preschool ; Children ; Confidence intervals ; Fundamental and applied biological sciences. Psychology ; Hospitalization ; Hospitals ; Humans ; Illnesses ; Immunization ; Infant ; Influenza ; Influenza Vaccines - immunology ; Influenza Vaccines - therapeutic use ; Influenza, Human - epidemiology ; Influenza, Human - immunology ; Influenza, Human - prevention &amp; control ; Japan - epidemiology ; Microbiology ; Mortality ; Observational studies ; Pediatrics ; Pharmaceuticals ; Prospective Studies ; Public health ; Seasons ; Vaccine ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, Inactivated - immunology ; Vaccines, Inactivated - therapeutic use</subject><ispartof>Vaccine, 2011-02, Vol.29 (9), p.1844-1849</ispartof><rights>Elsevier Ltd</rights><rights>2011 Elsevier Ltd</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Feb 17, 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</citedby><cites>FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1498110615?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=23871262$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21195802$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katayose, Masahiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Haneda, Takashi</creatorcontrib><creatorcontrib>Yamaguchi, Hideo</creatorcontrib><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Sato, Masatoki</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature &gt;38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</description><subject>Age</subject><subject>Age Factors</subject><subject>Allergy and Immunology</subject><subject>Applied microbiology</subject><subject>Biological and medical sciences</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Confidence intervals</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Hospitalization</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Infant</subject><subject>Influenza</subject><subject>Influenza Vaccines - immunology</subject><subject>Influenza Vaccines - therapeutic use</subject><subject>Influenza, Human - epidemiology</subject><subject>Influenza, Human - immunology</subject><subject>Influenza, Human - prevention &amp; control</subject><subject>Japan - epidemiology</subject><subject>Microbiology</subject><subject>Mortality</subject><subject>Observational studies</subject><subject>Pediatrics</subject><subject>Pharmaceuticals</subject><subject>Prospective Studies</subject><subject>Public health</subject><subject>Seasons</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</subject><subject>Vaccines, Inactivated - immunology</subject><subject>Vaccines, Inactivated - therapeutic use</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhiMEokvhJ4AiIcQpy4xjO86FClV8SZU4UCRultcZq16yTrGTiPLrcbSBol56suV53hnPvFMUzxG2CCjf7LezsdYH2jJY3tgWePug2KBq6ooJVA-LDTDJK47w_aR4ktIeAESN7ePihCG2QgHbFMPlFZXkHNnRzxQopXJw5Rj9bHoKY-mDWSJmpC7fXT9R-G3KtXR-Ke2V77tIoRxmimXyv0o7hER2WvL9J0lkUg48LR450yd6tp6nxbcP7y_PP1UXXz5-Pn93UVnRiLFypBpldxK5YKa2ZIRD14EC2alaNiB3UrYtdyTazmHHLai2FpzbBluinalPi9fHvNdx-DlRGvXBJ0t9bwINU9JK8lairOX9pAAhoWY8ky_vkPthiiG3oZG3ChEkikyJI2XjkFIkp6-jP5h4oxH0Yp3e63V-erFOI9PZuqx7sWafdgfq_qn-epWBVytgkjW9iyZYn265WjXI5MKdHTnK8509RZ2sp2Cp8zHbrLvB3_uVt3cy2N4Hn4v-oBtKt13rlAX667Jny5ohACrGoP4Dao_PtQ</recordid><startdate>20110217</startdate><enddate>20110217</enddate><creator>Katayose, Masahiko</creator><creator>Hosoya, Mitsuaki</creator><creator>Haneda, Takashi</creator><creator>Yamaguchi, Hideo</creator><creator>Kawasaki, Yukihiko</creator><creator>Sato, Masatoki</creator><creator>Wright, Peter F</creator><general>Elsevier Ltd</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20110217</creationdate><title>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</title><author>Katayose, Masahiko ; Hosoya, Mitsuaki ; Haneda, Takashi ; Yamaguchi, Hideo ; Kawasaki, Yukihiko ; Sato, Masatoki ; Wright, Peter F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c575t-fe878cb61452a3cea5f1fd0806d836706b66994fe59df1d4c0893544c719eeba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Age</topic><topic>Age Factors</topic><topic>Allergy and Immunology</topic><topic>Applied microbiology</topic><topic>Biological and medical sciences</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Confidence intervals</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Hospitalization</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Infant</topic><topic>Influenza</topic><topic>Influenza Vaccines - immunology</topic><topic>Influenza Vaccines - therapeutic use</topic><topic>Influenza, Human - epidemiology</topic><topic>Influenza, Human - immunology</topic><topic>Influenza, Human - prevention &amp; control</topic><topic>Japan - epidemiology</topic><topic>Microbiology</topic><topic>Mortality</topic><topic>Observational studies</topic><topic>Pediatrics</topic><topic>Pharmaceuticals</topic><topic>Prospective Studies</topic><topic>Public health</topic><topic>Seasons</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)</topic><topic>Vaccines, Inactivated - immunology</topic><topic>Vaccines, Inactivated - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katayose, Masahiko</creatorcontrib><creatorcontrib>Hosoya, Mitsuaki</creatorcontrib><creatorcontrib>Haneda, Takashi</creatorcontrib><creatorcontrib>Yamaguchi, Hideo</creatorcontrib><creatorcontrib>Kawasaki, Yukihiko</creatorcontrib><creatorcontrib>Sato, Masatoki</creatorcontrib><creatorcontrib>Wright, Peter F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katayose, Masahiko</au><au>Hosoya, Mitsuaki</au><au>Haneda, Takashi</au><au>Yamaguchi, Hideo</au><au>Kawasaki, Yukihiko</au><au>Sato, Masatoki</au><au>Wright, Peter F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2011-02-17</date><risdate>2011</risdate><volume>29</volume><issue>9</issue><spage>1844</spage><epage>1849</epage><pages>1844-1849</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><coden>VACCDE</coden><abstract>Abstract Objective To estimate the effectiveness of two doses of trivalent inactivated influenza vaccine (TIV) over six consecutive influenza seasons in a small community in Japan. Patients and methods A prospective, non-randomized, observational study of TIV effectiveness was performed involving children aged 6 months to 6 years accessing pediatric services in Soma and Shinchi, Japan. The total number of children under observation was 14,788. Each fall from 2002 to 2007 TIV was offered to all children with an average uptake of 52.9%. Influenza rapid diagnostic tests were performed to all children with respiratory symptoms and a temperature &gt;38 °C during each surveillance period. The efficacy of two doses of TIV was estimated by the relative risk of influenza illness and influenza associated hospitalizations and effectiveness by reduction in all respiratory illness in vaccinated and unvaccinated children. Results Influenza A occurred each year resulting in approximately one in five children in the unvaccinated group having an influenza A related clinic visit. For influenza A, two doses of TIV showed yearly efficacies that ranged from 42% to 69% with the highest efficacy during the 2002/2003 influenza season when the vaccine strains were well matched with the circulating viruses. The overall efficacy of two doses of TIV against influenza A and B associated illness was 52% and 59%, respectively. TIV also reduced the rate of the influenza associated hospitalizations attributable to both influenza A and B. Conclusions Vaccination with two doses of TIV was consistently effective in preventing influenza-associated clinic visits and hospitalizations.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><pmid>21195802</pmid><doi>10.1016/j.vaccine.2010.12.049</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2011-02, Vol.29 (9), p.1844-1849
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_864961636
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Age
Age Factors
Allergy and Immunology
Applied microbiology
Biological and medical sciences
Child, Preschool
Children
Confidence intervals
Fundamental and applied biological sciences. Psychology
Hospitalization
Hospitals
Humans
Illnesses
Immunization
Infant
Influenza
Influenza Vaccines - immunology
Influenza Vaccines - therapeutic use
Influenza, Human - epidemiology
Influenza, Human - immunology
Influenza, Human - prevention & control
Japan - epidemiology
Microbiology
Mortality
Observational studies
Pediatrics
Pharmaceuticals
Prospective Studies
Public health
Seasons
Vaccine
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Inactivated - immunology
Vaccines, Inactivated - therapeutic use
title The effectiveness of trivalent inactivated influenza vaccine in children over six consecutive influenza seasons
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T12%3A50%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effectiveness%20of%20trivalent%20inactivated%20influenza%20vaccine%20in%20children%20over%20six%20consecutive%20influenza%20seasons&rft.jtitle=Vaccine&rft.au=Katayose,%20Masahiko&rft.date=2011-02-17&rft.volume=29&rft.issue=9&rft.spage=1844&rft.epage=1849&rft.pages=1844-1849&rft.issn=0264-410X&rft.eissn=1873-2518&rft.coden=VACCDE&rft_id=info:doi/10.1016/j.vaccine.2010.12.049&rft_dat=%3Cproquest_cross%3E864961636%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1498110615&rft_id=info:pmid/21195802&rft_els_id=S0264410X10018220&rfr_iscdi=true